PakGent Bio Secures Tens of Millions in Series A Funding Led by Yuming Venture Capital

VCBeat has learned that Lejie Biotechnology (Suzhou) Co., Ltd. (“Lejie Bio”) recently completed its first round of strategic financing, amounting to tens of millions of yuan, with exclusive investment from Yuming Venture Capital. The funds will be used to sustain R&D investment in the field of high-end laboratory consumables and to promote product marketing following the commencement of operations at its second-phase production base.

Laijie Biotech, established in November 2020, specializes in the research and development, manufacturing, and sales of consumables for high-end life sciences and healthcare, dedicated to providing integrated solutions for medical consumables. Its product portfolio includes pipette tips, PCR tubes/plates, and cell culture consumables, which are primarily applied in biopharmaceutical fields such as basic scientific research, molecular diagnostics, vaccines, cell therapy, antibody drugs, and gene therapy.

Laijie Biotech operates a Class 100,000 cleanroom, a 3,000-square-meter production facility, and independent warehousing in Wuzhong District, Suzhou, with all materials being medical-grade. As a global brand, Laijie Biotech has successfully registered PakGent in more than 40 countries.^®Brand: Its product lines have been successfully exported to more than 40 countries and regions, including Europe, the United States, Canada, the Middle East, and the Asia-Pacific. It has sequentially obtained certifications such as CE, FDA, ISO 13485, ISO 9001, and Medical Device Quality Management System.

In August 2022, Laijie Biotechnology signed an agreement to establish its headquarters base for biomedical and high-end laboratory consumables, with a total construction area of approximately 40,000 square meters, in the Changshu Economic and Technological Development Zone. This project will further expand the company’s R&D and production capabilities for new products, bridge the technological gap in China’s high-end intelligent pipetting sector, break the monopoly held by foreign brands, and gradually achieve domestic substitution.

Ms. Ding Hongjuan, Founder of Laijie Biotech, brings over a decade of experience in manufacturing and global marketing within this field. Dr. Gao, Chief Application Scientist and Co-Founder, completed his postdoctoral fellowship at Harvard Medical School in Boston, USA, and has accumulated more than 20 years of research experience at renowned pharmaceutical R&D centers across the United States. Positioned as a global enterprise, Laijie Biotech aims to become a world-class brand.

Regarding this investment, Yuming Venture Capital stated: “We remain optimistic about the rapid development of China’s life sciences industry and actively focus on foundational technologies and product support in the upstream segment of the industrial chain. The high-end laboratory consumables industry is a high-value-added upstream sector, primarily applied in biopharmaceutical-related fields such as basic scientific research, molecular diagnostics, vaccines, and cell therapy. The physicochemical and biological properties of its products, as well as their precision, directly impact the success, failure, and efficiency of biotechnology R&D and applications. There remains a significant technological gap between domestic enterprises and overseas giants in this field, with the domestic high-end product market largely monopolized by foreign companies such as Corning, Thermo Fisher Scientific, and Sartorius. Laige Biotech’s core team possesses extensive industrialization capabilities accumulated over the long term and a comprehensive global marketing network. The company is committed to developing high-quality products that match the performance of leading international brands, offering more competitive solutions and continuously advancing the substitution of imported products.”

Meanwhile, we are optimistic about Laijie Biology’s capabilities and strategic planning under its “In China, For Global” initiative. Leveraging its industry influence, the company aims to establish a one-stop centralized procurement platform to serve European and American markets, while introducing high-end medical consumables and reagents from these regions to enrich the domestic product portfolio and build a premium brand in China.

“This exclusive investment holds strategic significance for both parties. Yuming Venture Capital will continue to facilitate connections between Laijie Bio and relevant industry clients, empower the company’s team building and financing arrangements, and assist the company in standardizing operations and implementing strategic planning with a view toward an initial public offering (IPO).”

Yuming Venture Capital is a private equity investment firm focused on two core sectors: healthcare and life sciences, and advanced manufacturing (AMAC Registration No.: P1074223). The team comprises professionals with composite backgrounds in investment banking, investing, and industry operations, possessing extensive experience in equity investment and deep expertise in capital markets. With a profound understanding of the growth patterns of startups and the ecosystem of capital markets, Yuming Venture Capital employs a dual-drive investment strategy combining venture capital investment with investment banking and industrial services, aiming to build a premier RMB-denominated fund brand.